Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
410.88 K
Value Traded
5.58 M
Short % Float
8.91%
Days to Cover
11.2
-8.96%Week
+6.06%1 Month
-32.75%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.29 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
702.14 M
Total Shares
93.60 M
Float Shares
63.89 M
Insiders
31.67%
Institutions
63.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KARD Catalyst Timeline
Dated clinical, regulatory and corporate events for Kardigan, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kardigan, Inc.
32Total events
15Upcoming
10Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 11
●R&D DayPresentation
Kardigan investor webcast at AHA Scientific Sessions presenting real-world and KATALYST-AV baseline data
aortic stenosissource ↗
▲Enrollment CompleteAtaciguatTrial
Completed enrollment in Phase 2b KATALYST-AV trial
moderate aortic stenosissource ↗
●Protocol AmendmentAtaciguatTrial
KATALYST-AV protocol amended to assess primary AVC endpoint at Week 48
aortic stenosissource ↗
●Management ChangeCorporate
Kristin Reinke appointed to Board of Directors and Audit Committee chair
●Management ChangeCorporate
Kristin Reinke appointed to Kardigan Board of Directors, chair of Audit Committee
●Quarterly UpdateCorporate
Reported financial results for the second quarter ended June 30, 2026
▲Trial InitiationDanicamtivTrial
Enrollment of the Phase 3 portion of KINSHIP-DCM is now underway
genetic dilated cardiomyopathy (DCM)source ↗
▲Enrollment CompleteDanicamtivTrial
Completed enrollment in Cohort 2 of Phase 2b KINSHIP-DCM trial
genetic dilated cardiomyopathysource ↗
●IpoCorporate
Closing of initial public offering with aggregate gross proceeds of $460 million
▲First Patient DosedTonlamarsenTrial
Randomized the first patient in KARDINAL-ASH in the second quarter
acute severe hypertension (ASH)source ↗
Past FDA Catalysts and PDUFA Decisions
How KARD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 26%
Micro Cap(rank 189 of 724)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ataciguat Small MoleculesNCT07001800 | Moderate Aortic Valve Stenosis | Phase 2/3 | RECRUITING | 1,276 | Sep 30, 2030 | ||||||
| Danicamtiv Small MoleculesNCT07771465 | Symptomatic Genetic Dilated Cardiomyopathy | Phase 3 | RECRUITING | 664 | Jan 1, 2033 | ||||||
| Tonlamarsen RNA-Based TherapiesNCT06864104 | Hypertension | Phase 2 | COMPLETED | 346 | Mar 17, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every KARD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRTG GPE, LLC10% Owner | BuyOffering | 3,125,000 14,866,868 held | $16.00 | 06/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KARD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 2.9 % | 195.59 M | 8.20 M |
Ownership Trends
KARD Short Interest
Shares sold short, counted twice a month.
8.91%
Short % of Float
of tradable shares sold short
5.7M
Shares Sold Short
+7.4% vs prior count
11.2 Very high
Days to Cover
trading days of normal volume to buy every short share back
508.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KARD ranks across every disease it competes in
Competitive Position is a premium feature
See how KARD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKARD News
-KARD
Nov 12, 2026▼ -9.9%on this news
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
Kardigan reported its third quarter 2026 financial results, highlighting significant progress in its clinical trials. Enrollment is complete in the Phase 2b KINSHIP-DCM trial for danicamtiv, with topline data expected in Q2 2027. Additionally, the company completed enrollment in the Phase 2b KATALYST-AV trial for ataciguat, with results anticipated in the second half of 2027.
Read more →-KARD
Nov 11, 2026▼ -2.1%today
Kardigan to Participate in the Jefferies Global Healthcare Conference
Kardigan, Inc. announced its participation in the 2026 Jefferies London Healthcare Conference. The fireside chat is scheduled for November 18 at 4:30 PM (GMT). A live webcast will be accessible on their website, with a replay available afterward. Kardigan focuses on developing treatments for cardiovascular diseases without approved therapies.
Read more →-KARD
Nov 6, 2026Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
Kardigan has completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat in aortic stenosis patients. The trial's primary endpoint will assess aortic valve calcium at Week 48, with topline data expected in the second half of 2027. New real-world data informs patient selection and potential endpoints for future trials.
Read more →-KARD
Sep 30, 2026Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Kardigan has appointed Kristin Reinke to its Board of Directors, where she will take on the role of chair of the Audit Committee. This strategic move is aimed at enhancing the company's governance and oversight capabilities. Reinke's experience is expected to contribute positively to Kardigan's leadership.
Read more →-KARD
Sep 2, 2026▼ -5.4%on this news
Kardigan to Present at Two September Investor Conferences
Kardigan, based in South San Francisco and Princeton, will present at two significant investor conferences: the 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference. This participation aims to enhance the company's visibility and engage with potential investors.
Read more →-KARD
Aug 11, 2026Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardigan, Inc. has announced its financial results for the second quarter of 2026, ending on June 30. Alongside the financial data, the company has shared recent updates regarding its business operations. The report reflects the company's ongoing activities and performance in the biopharma sector.
Read more →-KARD
Jun 22, 2026Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan has successfully completed its initial public offering (IPO), with the underwriters fully exercising their option to purchase additional shares. This development reflects a positive outlook and strong demand from investors. The IPO is expected to enhance Kardigan's financial position and growth potential.
Read more →-KARD
Jun 18, 2026Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan, Inc. has announced the pricing of its initial public offering (IPO) of 25 million shares at $16 each, aiming to raise $400 million. The shares will begin trading on the Nasdaq under the ticker 'KARD' on June 18, 2026, with the offering expected to close on June 22, 2026. Kardigan focuses on developing precision therapeutics for cardiovascular diseases lacking approved treatments.
Read more →-KARD
Mar 28, 2026Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
Kardigan announced positive results from its Phase 2 trial of tonlamarsen for uncontrolled hypertension. The drug showed significant reductions in plasma angiotensinogen and systolic blood pressure. These findings support the launch of a Phase 2b trial targeting acute severe hypertension. Tonlamarsen was well-tolerated with a favorable safety profile.
Read more →-KARD
Mar 17, 2026Kardigan Announces Multiple Presentations at ACC.26 from its Late-Stage Portfolio of Personalized Cardiovascular Medicines
Kardigan will present multiple studies at the ACC.26, including late-breaking Phase 2 data on tonlamarsen for uncontrolled hypertension. Prolaio, a subsidiary, will showcase research on continuous monitoring and novel biomarkers in cardiovascular care. These presentations highlight Kardigan's commitment to advancing cardiovascular therapeutics and improving patient outcomes.
Read more →-KARD
Jan 6, 2026Kardigan Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference and Provides Corporate Update for 2026
Kardigan has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference and provided a corporate update for 2026. The company is poised for significant advancements in cardiovascular drug development, with multiple clinical data readouts expected across its late-stage programs. Additionally, Andy Pasternak has been appointed as chief strategy officer, enhancing the leadership team as Kardigan aims to address unmet needs in cardiovascular care.
Read more →-KARD
Nov 7, 2025Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients with Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025
Kardigan presented positive Phase 2 data on ataciguat for patients with moderate calcific aortic valve stenosis at the American Heart Association Scientific Sessions 2025. The results indicated that ataciguat reduced aortic valve calcium and improved cardiac function compared to placebo. The findings suggest a potential shift from watchful waiting to a disease-modifying treatment for this condition.
Read more →-KARD
Oct 14, 2025Kardigan Raises $254 Million Series B to Advance Late-Stage Portfolio of Personalized Cardiovascular Medicines
Kardigan has successfully raised $254 million in Series B financing to advance its late-stage portfolio targeting specific types of dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis. The funding will facilitate multiple data readouts starting in 2026. Kardigan aims to redefine cardiovascular disease treatment by addressing root causes rather than just managing symptoms.
Read more →-KARD
Sep 29, 2025Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025
Kardigan announced positive Phase 2a data for danicamtiv in patients with genetic dilated cardiomyopathy (DCM) at the HFSA Annual Scientific Meeting 2025. The results demonstrated significant improvements in left ventricular ejection fraction and left atrial function index. Danicamtiv was well tolerated, with no drug-related adverse events leading to discontinuation. The findings support ongoing development and future trials.
Read more →About Kardigan, Inc.
HeadquartersC/O KARDIGAN, INC., SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE
Trade the next KARD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime